SOX2 Silencing in Glioblastoma Tumor‐Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity

Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express several genes typical of normal neural stem cells. One of them, SOX2, is a master gene involved in sustaining self‐renewal of several stem cells, in particular neural stem cells. To investigate its role in the aberrant growth of glioblastoma, we silenced SOX2 in freshly derived glioblastoma tumor‐initiating cells (TICs). Our results indicate that SOX2 silenced glioblastoma TICs, despite the many mutations they have accumulated, stop proliferating and lose tumorigenicity in immunodeficient mice. SOX2 is then also fundamental for maintenance of the self‐renewal capacity of neural stem cells when they have acquired cancer properties. SOX2, or its immediate downstream effectors, would then be an ideal target for glioblastoma therapy. STEM CELLS 2009;27:40–48

[1]  P. Walker,et al.  Role of Sox2 in the development of the mouse neocortex. , 2006, Developmental biology.

[2]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[3]  J. Crowley,et al.  Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy , 2007, The Journal of experimental medicine.

[4]  F. Gage,et al.  In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem cells in the adult hippocampus. , 2007, Cell stem cell.

[5]  G. Stassi,et al.  Cancer stem cells – old concepts, new insights , 2008, Cell Death and Differentiation.

[6]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[7]  Pier Paolo Pandolfi,et al.  Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain , 2004, Development.

[8]  Alexei A. Sharov,et al.  Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells , 2007, Nature Cell Biology.

[9]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[10]  Jessica Mariani,et al.  Impaired generation of mature neurons by neural stem cells from hypomorphic Sox2 mutants , 2008, Development.

[11]  Jialing Yuan,et al.  Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. , 2007, Cancer research.

[12]  Kristi A. Hohenstein,et al.  Regulation of Self‐Renewal and Pluripotency by Sox2 in Human Embryonic Stem Cells , 2008, Stem cells.

[13]  L. Muzio,et al.  Effects of Emx2 inactivation on the gene expression profile of neural precursors , 2006, The European journal of neuroscience.

[14]  S. Paek,et al.  Expression of Sox2 in mature and immature teratomas of central nervous system , 2007, Modern Pathology.

[15]  L. Bridges,et al.  EPIDEMIOLOGY OF CENTRAL NERVOUS SYSTEM TUMORS IN CHILDREN AND YOUNG ADULTS (0–29 YEARS), YORKSHIRE, UNITED KINGDOM , 2004, Pediatric hematology and oncology.

[16]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Pevny,et al.  SOX2 Functions to Maintain Neural Progenitor Identity , 2003, Neuron.

[18]  M. Perera,et al.  Regulatory genes controlling cell fate choice in embryonic and adult neural stem cells , 2004, Journal of neurochemistry.

[19]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[20]  J. Reis-Filho,et al.  Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer , 2007, Modern Pathology.

[21]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[22]  M. Capra,et al.  Emx2 in adult neural precursor cells , 2001, Mechanisms of Development.

[23]  S. Stevanović,et al.  Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy , 2007, British Journal of Cancer.

[24]  S. Ferrini,et al.  Glioma immunotherapy by IL‐21 gene‐modified cells or by recombinant IL‐21 involves antibody responses , 2007, International journal of cancer.

[25]  S. Orkin,et al.  An Extended Transcriptional Network for Pluripotency of Embryonic Stem Cells , 2008, Cell.

[26]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.